Cargando…

HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination

BACKGROUND AND AIMS: Harm reduction strategies have been shown to decrease the incidence of human immunodeficiency virus (HIV) infection in people who inject drugs (PWID), but the results have been inconsistent when it comes to prevention of hepatitis C virus (HCV) infection. We aimed to examine the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valencia La Rosa, Jorge, Ryan, Pablo, Alvaro-Meca, Alejandro, Troya, Jesús, Cuevas, Guillermo, Gutiérrez, Jorge, Moreno, Santiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169909/ https://www.ncbi.nlm.nih.gov/pubmed/30281616 http://dx.doi.org/10.1371/journal.pone.0204795

Ejemplares similares

Recurring Severe Injection-Related Infections in People Who Inject Drugs and the Need for Safe Injection Sites in Madrid, Spain
por: Valencia, Jorge, et al.
Publicado: (2021)

Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004–2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions
por: Sobrino-Vegas, Paz, et al.
Publicado: (2014)

Gender-based vulnerability in women who inject drugs in a harm reduction setting
por: Valencia, Jorge, et al.
Publicado: (2020)

Perinatal HCV Transmission Rate in HIV/HCV Coinfected women with access to ART in Madrid, Spain
por: Domínguez-Rodríguez, Sara, et al.
Publicado: (2020)

Risk Factors of HCV Seroconversion in Hemodialysis Patients in Tabriz, Iran
por: Somi, Mohammad Hossein, et al.
Publicado: (2014)

Is HCV elimination possible in prison?
por: Crespo, J., et al.
Publicado: (2017)

Remaining challenges in HCV elimination
por: Capraru, Camelia, et al.
Publicado: (2021)

HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study
por: Ryan, Pablo, et al.
Publicado: (2021)

HCV elimination among people who inject drugs. Modelling pre- and post–WHO elimination era
por: Gountas, Ilias, et al.
Publicado: (2018)

Elimination of HCV in Russia: Barriers and Perspective
por: Isakov, Vasily, et al.
Publicado: (2022)

Epidemiology and Elimination of HCV-Related Liver Disease
por: Pradat, Pierre, et al.
Publicado: (2018)

Eliminating HCV: a marathon, not a sprint
por: The Lancet Gastroenterology & Hepatology
Publicado: (2020)

Combined COVID-19 vaccination and HIV and hepatitis C virus screening intervention for high-risk populations at a mobile testing unit in Madrid, Spain
por: Valencia, Jorge, et al.
Publicado: (2022)

Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways
por: Mangia, Alessandra, et al.
Publicado: (2021)

HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates
por: Lens, Sabela, et al.
Publicado: (2022)

Impact of COVID-19 on global HCV elimination efforts
por: Blach, Sarah, et al.
Publicado: (2021)

Perspectives of hepatitis C virus (HCV) elimination in Poland
por: Flisiak, Robert, et al.
Publicado: (2019)

Impact of the COVID-19 pandemic on HCV elimination in Spain
por: Buti, Maria, et al.
Publicado: (2021)

Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020
por: Feld, Jordan J., et al.
Publicado: (2021)

HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
por: Garbuglia, Anna Rosa, et al.
Publicado: (2014)

The correlation of HCV RNA and HCV core antigen in different genotypes of HCV
por: Xiang, Yu, et al.
Publicado: (2018)

HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons
por: Flisiak, Robert, et al.
Publicado: (2022)

Outcomes of an HCV elimination program targeting the Viennese MSM population
por: Jachs, Mathias, et al.
Publicado: (2021)

HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated Pathogenesis
por: Medvedev, Regina, et al.
Publicado: (2016)

MicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection
por: Brochado-Kith, Óscar, et al.
Publicado: (2019)

HCV, HIV AND HBV rapid test diagnosis in non-clinical outreach settings can be as accurate as conventional laboratory tests
por: Muñoz-Chimeno, Milagros, et al.
Publicado: (2023)

HCV and lichen planus: HCV and lichen planus
por: Rebora, Alfredo
Publicado: (2011)

Pilot Outreach Program in Remedis—The Promising Step toward HCV Elimination among People Who Inject Drugs
por: Krekulová, Laura, et al.
Publicado: (2022)

Are We on the Right Track for HCV Micro-Elimination? HCV Management Practices in Dialysis Centers in Poland—A National Cross-Sectional Survey
por: Czarnecka, Paulina, et al.
Publicado: (2023)

355. Barriers for Hepatitis C Elimination in HIV/HCV Coinfected Patients
por: Espinoza, Joe, et al.
Publicado: (2019)

Key Role of Multidisciplinary Collaboration towards Global Elimination of HCV Infection
por: Krekulova, Laura, et al.
Publicado: (2022)

Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV
por: Jahan, Shah, et al.
Publicado: (2011)

All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings
por: Berenguer, Juan, et al.
Publicado: (2018)

The Burgeoning HIV/HCV Syndemic in the Urban Northeast: HCV, HIV, and HIV/HCV Coinfection in an Urban Setting
por: Morano, Jamie P., et al.
Publicado: (2013)

Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients
por: Long, Lu, et al.
Publicado: (2014)

HCV core antigen plays an important role in the fight against HCV as an alternative to HCV‐RNA detection
por: Wang, Yuhan, et al.
Publicado: (2021)

SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination
por: Crespo, Javier, et al.
Publicado: (2021)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
por: Vigón, Lorena, et al.
Publicado: (2019)

HIV/HCV co-infection and associated risk factors among injecting drug users in Dar es Salaam, Tanzania: potential for HCV elimination
por: Leyna, Germana Henry, et al.
Publicado: (2019)

Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era
por: Alvaro-Meca, Alejandro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9q53bdv5rpnb911dbptpidh12l